But we noticed that on September 9, 2022, Pfizer had amended its disclosures. So being late. . . let us be. . . accurate. Grin.
Here it is, among other matters:
. . .Drug Pricing, Support of Biosimilars, Out-of-Pocket Costs, Rebate Reform, Vaccine Infrastructure/HR 3656 Excise Tax- S.3087, Antimicrobial Resistance/HR 3932/PASTEUR Act, COVID Relief Package/Appropriations, PDUFA. . . .
Medicare Part D support for access to treatments for obesity, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, Government Negotiation in Medicare. . . .
Comprehensive Corporate Tax Reform, International Tax Reform, OECD Profit Allocation, U.S. Manufacturing Credits, Build Back Better Act, Minimum Tax. . . .
NAFTA/USMCA, Foreign Market Access issues (including IPR), International Supply Chain/Buy America - harmonize international drug manufacturing standards, Global Access to Medicines. . . .
TRIPS Waiver, General IP Issues, Bayh-Dole March-In Rights. . . .
Now you know. Sorry about the delay. . . smile.
नमस्ते
No comments:
Post a Comment